(Q43812580)

27 November 2017

Effects of the 5HT antagonist cyproheptadine on neuropsychological function in chronic schizophrenia (English)

1 reference

27 November 2017

1 reference

1 reference

4

1 reference

27 November 2017

I B Chaudhry

1

1 reference

27 November 2017

S D Soni

series ordinal

2

1 reference

27 November 2017

J S E Hellewell

series ordinal

3

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

27 November 2017

Schizophrenia Research

1 reference

27 November 2017

53

1 reference

27 November 2017

1-2

1 reference

27 November 2017

17-24

1 reference

M100907, a selective 5-HT2A receptor antagonist and a potential antipsychotic drug, facilitates N-methyl-D-aspartate-receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro.

27 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900165-7

7 January 2021

Cyproheptadine in treatment-resistant chronic schizophrenics with prior negative response to fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900165-7

7 January 2021

The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900165-7

7 January 2021

Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900165-7

7 January 2021

Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900165-7

7 January 2021

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900165-7

7 January 2021

Local and distributed effects of apomorphine on fronto-temporal function in acute unmedicated schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900165-7

7 January 2021

Regional brain activity in chronic schizophrenic patients during the performance of a verbal fluency task.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900165-7

7 January 2021

Performance of schizophrenic patients on putative neuropsychological tests of frontal lobe function.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900165-7

7 January 2021

Relations between neuropsychological performance and brain morphological and physiological measures in monozygotic twins discordant for schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900165-7

7 January 2021

Cognitive impairment and negative symptoms in geriatric chronic schizophrenic patients: a follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900165-7

7 January 2021

The Usefulness of the Clinical Tests of the Sensorium

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900165-7

7 January 2021

Serotonin-dopamine interaction and its relevance to schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900165-7

7 January 2021

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900165-7

7 January 2021

A standardized psychiatric assessment scale for rating chronic psychotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900165-7

7 January 2021

Cyproheptadine augmentation of haloperidol in chronic schizophrenic patients: a double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900165-7

7 January 2021

Patterns of cerebral blood flow in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900165-7

7 January 2021

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900165-7

7 January 2021

Functional neuroanatomy of antisaccade eye movements investigated with positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900165-7

7 January 2021

Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900165-7

7 January 2021

Trail Making Test Results for Normal and Brain-Damaged Children

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900165-7

7 January 2021

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900165-7

7 January 2021

Antipsychotic drug doses and neuroleptic/dopamine receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900165-7

7 January 2021

Treatment of chronic schizophrenia with cyproheptadine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900165-7

7 January 2021

Treatment of chronic schizophrenia with cyproheptadine: a double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900165-7

7 January 2021

Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900165-7

7 January 2021

Why do schizophrenic patients refuse to take their drugs?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900165-7

7 January 2021

Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900165-7

7 January 2021

Cyproheptadine treatment in neuroleptic-induced akathisia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900165-7

7 January 2021

10.1016/S0920-9964(01)00165-7

Identifiers

DOI

1 reference

27 November 2017

1 reference